Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Executive Summary
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
You may also be interested in...
Japan's Taisho Struggles Overseas In Q1 As Domestic Sales Recover
Japan's Taisho posted OTC sales down 5% its first quarter, as turnover fell double-digits in its Europe and Americas region due to the ongoing impact of the COVID-19 pandemic.
People On The Move: Appointments At UPSA, Bionorica And MHRA
The latest European consumer health people news: Sanofi Consumer Healthcare's Van Rycke named CEO of UPSA; Bionorica's global business head steps down; MHRA names its first chief safety officer.
Taisho's OTC Sales Fall In Japan As Consumers Stay At Home
A drop in socializing and travelling in Japan due to the COVID-19 pandemic hit demand for Taisho's leading consumer health brands in its latest reporting period.